^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BTG-002814

    i
    Other names: BTG-002814, vandetanib-eluting radiopaque beads
    Associations

    News

    Trials
    Company:
    Boston Scientific, UCL Cancer Institute
    Drug class:
    RET inhibitor, VEGFR-2 inhibitor, EGFR antagonist
    Related drugs:
    Associations

    News

    Trials
    3years
    Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. (PubMed, Anticancer Drugs)
    Incubation of tumour spheroids with VERB led to sustained growth inhibition equivalent to the effect of free drug. We conclude that vandetanib has both antiangiogenic and direct anticancer activity against HCC cells even in hypoxic conditions, warranting the further evaluation of VERB as novel anticancer agents.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BCL2L11 (BCL2 Like 11)
    |
    Caprelsa (vandetanib) • BTG-002814